

Publications List

A / Prof Gavin Marx

As at : 06/02/2017

Li, B., Barnes, T., Chan, D., Naidoo, J., Lee, A., Khasraw, M., **Marx, G.**, Kris, M., Clarke, S., Drilon, A., Pavlakis, N. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non small-cell lung cancers: A meta-analysis of randomized trials. *Lung Cancer*, 102, 21-27 2016

Roger von Moos, Jean Jacques Body, Blair Egerdie, Alison Stopeck, Janet Brown, Lesley Fallowfield, Donald L. Patrick, Charles Cleeland, Danail Damyanov, Felipe Salvador Palazzo, **Gavin Marx**, Ying Zhou, Ada Braun, Arun Balakumaran, Yi Qian. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. *Supportive Care in Cancer*. March 2016

Kate Lynette Mahon, Hui-Ming Lin, Calan Spielman, Michelle Lee-Ng, Howard Gurney, Girish Mallesara, Martin R. Stockler, Karen P. Briscoe, **Gavin M. Marx**, Samuel N. Breit, David A. Brown, Lisa Horvath. Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC). *J Clin Oncol* 34, 2016 (suppl; abstr 5039)

Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, **Marx G**, Vaishampayan U, George S, Schwartz J, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Final Analysis of COMET-2: Cabozantinib versus Mitoxantrone/Prednisone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients With Moderate to Severe Pain Who Were Previously Treated With Docetaxel and Abiraterone and/or Enzalutamide. *ASCO GU* 2015

David Chan, Jennifer Mary McLachlan, Megan Crumbaker, **Gavin M. Marx**; Royal North Shore Hospital, St. Leonards, Australia; Northern Haematology and Oncology Group, Sydney, Australia. Pretreatment neutrophil/lymphocyte ratio (NLR) prior to steroids as a prognostic factor in metastatic castrate refractory prostate cancer (mCRPC) patients treated with taxanes. *J Clin Oncol* 33, 2015 (suppl 7; abstr 273) *ASCO GU* 2015

Hovey E, de Souza P, **Marx G**, Parente P, Rapke T, Hill A, Bonaventura A, Michele A, Craft P, Abdi E, Lloyd A; on behalf of the MOTIF investigators. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. *Support Care Cancer*. 2013 Dec 17.

Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, **Marx G**, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. *J Clin Oncol*. 2013 Oct 20;31(30):3800

McLachlan JM, **Marx GM**, Bridgman M. Severe symptomatic hypocalcaemia following a single dose of denosumab. *Med J Aust*. 2013 Aug 19;199(4):242-3.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, **Marx G**, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. *Support Care Cancer*. 2013 Dec;21(12):3497-507.

Won AC, Gurney H, **Marx G**, De Souza P, Patel MI. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. *BJU Int*. 2013 Aug;112(4):E250-5.

Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., **Marx, G.**, Cullen, M., Kerestes, Z., Pavlakis, N. (2012), The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. *Lung cancer (Amsterdam, Netherlands)*. 75(2), 248-54. 2012

Kao, S. C.-H., Hovey, E. and **Marx, G**. Second-line therapy for castrate-resistant prostate cancer: A literature review. *Asia-Pacific Journal of Clinical Oncology*, 7: 212–223. 2011

Tebbutt, N, Murphy, F, Zannino, D, Wilson, K, Cummins, M, Abdi, E, Strickland, A, Lowenthal, R, **Marx, G**, Karapetis, C, Shannon, J, Goldstein, D, Nayagam, S, Blum, R, Chantrill, L, Simes, R, Price, T, Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. *Annals of Oncology*. 2011

Christos S Karapetis, Kerry A Cheong, Desmond Yip, Andrew H Strickland, Christopher Steer, **Gavin Marx**, Sonia Yip, Kathryn Chrystal, Peter G Harper. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. *Asia-Pacific Journal of Clinical Oncology*. Volume 6, Issue 4, pages 298–305, December 2010

Publications List

A / Prof Gavin Marx

As at : 06/02/2017

Diana Adams and **Gavin Marx**. Daily Life As an Australian Medical Oncologist. *Journal of Oncology Practice*, Vol 6, No 3 (May), 2010: pp. 146-148.

C. B. Steer, **G. M. Marx**, N. Singhal, M. McJannett, D. Goldstein, R. Prowse. Cancer in older people: a tale of two disciplines
Internal Medicine Journal. Volume 39, Issue 11, Date: November 2009, 39(11) Pages: 771-775

M. Khasraw¹, N. Pavlakis¹, S. McCowatt^{1,2}, C. Underhill³, S. Begbie⁴, P. de Souza⁵, A. Boyce⁶, F. Parnis⁷, V. Lim¹, R Harvie¹ and **G Marx**. Multicentre Phase I/II Study of PI-88, a Heparanase Inhibitor in Combination with Docetaxel in Patients with Metastatic Castrate- Resistant Prostate Cancer. *Annals of Oncology*. Nov 2009

Liangli Zhao¹, Brian Y. Lee¹, David A. Brown³, Mark P. Molloy⁴, **Gavin M. Marx**⁵, Nick Pavlakis⁵, Michael J. Boyer⁶, Martin R. Stockler⁶, Warren Kaplan², Samuel N. Breit³, Robert L. Sutherland¹, Susan M. Henshall¹ and Lisa G. Horvath
Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. *Cancer Research* 69, 7696, October 1, 2009

Pavlakis N, **Marx G**, White S, Lee CW, Khasraw M. Anti-angiogenic therapy for lung cancer (Protocol). *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD008047. DOI: 10.1002/14651858.CD008047.

Elizabeth Hovey¹, **Gavin Marx**², Andrew Kneebone³, Manish Patel⁴ and Jeremy Shapiro An Australian Clinical Perspective: Management of Hormone Refractory (Androgen-Independent) Prostate Cancer. *Asia Pacific Journal of Oncology and Haematology* 2009

Gavin M. Marx, Nick Pavlakis, Sally McCowatt, Stephen Begbie, Craig Underhill, Adam Boyce, David Bell, Phillip Katelaris, Rozelle Harvie, Chris Ward. A Phase II Trial of Docetaxel and Thalidomide in Patients with Metastatic Androgen Independent Prostate Cancer. The ProTaT Trial.
Manuscript in preparation.

Rozelle Harvie MSc^{1,2}, Florian Paturi¹, Robyn Taylor BAppSci², Ross Davey PhD^{1,2}, Rick Abraham³, **Gavin Marx**², Martin Cullen², Zoltan Kereses PhD^{1,2}, and Nick Pavlakis^{1,2}. The predictive role of serum VEGF in an advanced malignant mesothelioma (MM) patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine . Manuscript in preparation.

M. Khasraw and **Gavin Marx**. Chemotherapy in the elderly. *Cancer Forum*. Mar 2008. Vol 32 Issue1.

Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., **Marx, G.**, Smith, G. The utility of FDG-PET in the preoperative staging of esophageal cancer. *Diseases of the Esophagus*. 2008; 21:389-394.